GDP regimen as salvage treatment for relapsed refractory non-Hodgkin's lymphoma

( views:245, downloads:0 )
Author:
ZHAO Jin(Department of Hematology, Affiliated Cancer Hospital of Shanxi Medical University, Taiyuan 030013, China)
WANG Yan-li(Department of Hematology, Affiliated Cancer Hospital of Shanxi Medical University, Taiyuan 030013, China)
HAN Wei-er(Department of Hematology, Affiliated Cancer Hospital of Shanxi Medical University, Taiyuan 030013, China)
ZHENG Yu-ping(Department of Hematology, Affiliated Cancer Hospital of Shanxi Medical University, Taiyuan 030013, China)
FENG Kai-chao(Department of Hematology, Affiliated Cancer Hospital of Shanxi Medical University, Taiyuan 030013, China)
ZHAO Zhi-qiang(Department of Hematology, Affiliated Cancer Hospital of Shanxi Medical University, Taiyuan 030013, China)
SU Li-ping(Department of Hematology, Affiliated Cancer Hospital of Shanxi Medical University, Taiyuan 030013, China)
WANG Jun(Department of Hematology, Affiliated Cancer Hospital of Shanxi Medical University, Taiyuan 030013, China)
MA Li(Department of Hematology, Affiliated Cancer Hospital of Shanxi Medical University, Taiyuan 030013, China)
HE Jian-xia(Department of Hematology, Affiliated Cancer Hospital of Shanxi Medical University, Taiyuan 030013, China)
WANG Lie-yang(Department of Hematology, Affiliated Cancer Hospital of Shanxi Medical University, Taiyuan 030013, China)
LI Xi(Department of Hematology, Affiliated Cancer Hospital of Shanxi Medical University, Taiyuan 030013, China)
Journal Title:
Journal of Leukemia & Lymphoma
Issue:
Volume 21, Issue 08, 2012
DOI:
10.3760/cma.j.issn.1009-9921.2012.08.007
Key Word:
Lymphoma, non-Hodgkin; Antineoplastic combined chemotherapy protocols;Recurrence; Refractory

Abstract: Objective To study the effect and safety of GDP regimens (gemcitabine,cisplatin,dexamethasone) as salvage chemotherapy in relapsed refractory non-Hodgkin’s lymphoma (NHL).Methods Clinical response and adverse effects of 34 NHL patients treated by GDP regimens were analyzed retrospectively.Results The overall response rate (ORR) was 52.9 % (18/34),there was no statistic difference between ORR in relapsed NHL [72.7 % (8/11)] and that in refractory ones [43.5 % (10/23)](P =0.11).The ORR for B-NHL was 64.0 % (16/25),while for T-NHL was 22.2 % (2/9),there was no statistic difference between them (P =0.052).The ORR for low risks groups was 66.7 % (6/9),while it for intermediate-risk and high-risk ones were 55.6 % (10/18) and 28.6 % (2/7),respectively,the effect of GDP regimens for low-risk group was better for high-risk ones,but there was no statistic difference (P =0.349).The incedience of Ⅲ-Ⅳ granulopenia reduced was 23.5 % (8/34) and there were no Ⅲ-Ⅳ gastrointestinal adverse reactions or liver and kidney toxicity.Conclusion GDP regimens were efficient and less toxic as second-line salvage chemotherapy.

  • [1]Gisselbrecht C,Glass B,Mounier N,et al.Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.J Clin Oncol,2010,28:4184-4190.
  • [2]范云,黄志煜,罗吕宏,等.MINE方案治疗复发或耐药的侵袭性非霍奇金淋巴瘤临床观察.癌症,2005,24:1503-1506.
  • [3]Plunkett W,Huang P,Searcy CE,et al.Gemcitabine:preclinical pharmacology and mechanisms of action.Semin Oncol,1996,23:3-15.
  • [4]Fossà A,Santoro W,Hiddemann L,et al.Gemcitabine as a single in the treatment of relapse or refractory aggressive non-Hodgkin’slymphoma.J Clin Oncol,1999,17:3786-3792.
  • [5]Zinzani PL,Venturini F,Stefoni V,et al.Gemcitabine as single agent in pretreated T-cell lymphoma patients:evaluation of the long-term outcome.Ann Oncol,201 O,21:860-863.
  • [6]Crump M,Baetz T,Couban S,et al.Gemcitabine,dexamethasone,and cisplatin in patients with recurrence or refractory aggressive histology B-cell non-Hodgkin’s lymphoma a phase Ⅱ study by the Nation Cancer Institute of Canada Clinical Trials Group (NCIC-CTG).Cancer,2004,101:1835-1842.
  • [7]Aribi M,Mesli N,Remla N,et al.Gemcitahine and treatment of diffuse large B-cell lymphoma in relapsed or refractory elderly patients:a prospective randomized trial in Algeria.J Cancer Res Ther,2010,6:41-46.
  • [8]宋诸臣,杨磊,曹永峰,等.GDP方案节拍化疗治疗复发难治性非霍奇金淋巴瘤28例.白血病·淋巴瘤,2011,20:241-243.
  • [9]潘战和,苏安,黄慧强,等.GDP方案治疗复发和难治性中高度恶性非霍奇金淋巴瘤.白血病·淋巴瘤,2010,19:88-90.
  • [10]何永明.吉西他滨联合方案治疗复发或难治性非霍奇金淋巴瘤5例.白血病·淋巴瘤,2006,15:49-50.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn